Regeneron Forecasts Mid-Teens R&D Expense Growth for 2027 and $1B Sanofi Payment in Q4
Regeneron Pharmaceuticals (REGN) reported strong third-quarter performance, attributed to robust commercial execution and a diverse product pipeline. Management expressed confidence in the company's current trajectory and long-term growth potential driven by ongoing clinical developments. Looking ahead, the company anticipates a significant increase in research and development spending, projecting mid-teens percentage growth by 2027. Additionally, Regeneron expects to record a $1 billion upfront payment from Sanofi during the fourth quarter, providing a substantial boost to its near-term cash position.
Topics: commercial execution earnings report pipeline development quarterly performance